Webinar News

The Member Alert webinar you just received 2020 EMWA position statement on predatory journals; EMWA is proud to announce the posting of the Romanian translation of the EMWA position statement on predatory journals. To read the statement, please click here.

Predatory journals are entities that prioritize self-interest at the expense of scholarship and are characterized by false or misleading information, deviation from best editorial and publication practices, a lack of transparency, and/or the use of aggressive and indiscriminate solicitation practices.

The definition put forward by the group is as follows:

"Predatory journals and publishers are entities that prioritize self-interest at the expense of scholarship and are characterized by false or misleading information, deviation from best editorial and publication practices, a lack of transparency, and/or the use of aggressive and indiscriminate solicitation practices.”

To raise awareness among non-English speakers about the responsibilities of medical writers and publication professionals concerning this significant issue, EMWA has initiated the translation of this statement into European languages.

EMWA is proud to announce the posting Romanian translation of the JPS by Georgiana Orbeanu and Carmen Schmechel. For a list of other EMWA translations, please click here.

Ambassador’s Programme

The American Medical Writers Association (AMWA), the European Medical Writers Association (EMWA), and the International Society for Medical Publication Professionals (ISMPP) recognize the challenges to scientific publication faced by journal editors and medical writing professionals. To address these challenges, AMWA, EMWA, and ISMPP are collaborating to develop guidelines that have helped define the characteristics of a predatory journal.

By joining with AMWA and ISMPP, EMWA is developing and publishing the Joint Position Statement on Predatory Journals. The statement is aimed at medical writing professionals to help them recognize predatory journals and avoid them.

The group of 43 participants, consisting of members of industry organizations, society and commercial publishers, research institutes, libraries, policymakers, and other key stakeholders, provided answers to 28 questions, and engaged in 12-months of discussion to develop the document, followed by 10 rounds of feedback and revision.

EMWA is proud to announce the posting of a Romanian translation of the Joint Position Statement on Predatory Journals. To read the statement, please click here.

We are pleased to announce the posting Romanian translation of the JPS by Georgiana Orbeanu and Carmen Schmechel. For a list of other EMWA translations, please click here.

To read the statement, please click here.

Member News

We invite you to join us on the 9th of January 2020 at 14:00-15:00 CET for our webinar on presentation skills. As medical communication specialists, whether designing slides for someone else or for our own use, we all want to create easily readable and professional-looking slides. Do you have a document-oriented slide? You'll find some useful principles and advice from our new slide toolkit. Please note that this will be a private company webinar.

To read the statement, please click here.

JPS Translation

We are currently looking for translators. If you would like to volunteer please contact aspscientist@gmail.com.

We are proud to announce the posting Romanian translation of the JPS by Georgiana Orbeanu and Carmen Schmechel. For a list of other EMWA translations, please click here.

To read the statement, please click here.

EMWA Newsblast - January 2020

Preparation for the World Congress of Medical Journal Editors, Chicago - August 2020

International Committee of Medical Journal Editors Updated Guidance

NIH Data Management and Sharing Activities Related to Public Access

Certificates of Confidentiality

ICH and EC Updates

European Union Directive 2011/69/EU on markets in financial instruments, market infrastructures and related markets

FDA's statement on the agency’s efforts to protect patients through post-market drug safety surveillance practices

FDA guidance on adaptive trial design released

EMA communication: Interactive timeline describing the journey of a medicine for human use authorised through EMA market access procedures

Pharmacovigilance 2030 published

Review of Xeljanz (tofacitinib) - CHMP Opinion (to be used with caution in patients at high risk of blood clots)

Available at: https://www.emwa.org/newsletter-archives/